Vasomodulation by skeletal muscle-derived nitric oxide requires α-syntrophin-mediated sarcolemmal localization of neuronal nitric oxide synthase

Gail D. Thomas, Philip W. Shaul, Ivan S. Yuhanna, Stanley C. Froehner, Marvin E. Adams

Research output: Contribution to journalArticle

103 Citations (Scopus)

Abstract

Neuronal nitric oxide synthase (nNOS) is abundantly expressed in skeletal muscle where it associates with the dystrophin complex at the sarcolemma by binding to the PDZ domain of α-syntrophin. Nitric oxide (NO) produced by skeletal muscle nNOS is proposed to regulate blood flow in exercising muscle by diffusing from the skeletal muscle fibers to the nearby microvessels where it attenuates α-adrenergic vasoconstriction. In the present study, we hypothesized that sarcolemmal localization of nNOS is a critical determinant of the vasoregulatory effect of skeletal muscle-derived NO. To test this hypothesis, we performed experiments in α-syntrophin null mice and in transgenic mice expressing a mutated α-syntrophin lacking the PDZ domain (ΔPDZ), both of which are characterized by reduced sarcolemmal nNOS. We found that modulation of α-adrenergic vasoconstriction was greatly impaired in the contracting muscles of the α-syntrophin null mice and transgenic ΔPDZ mice compared with wild-type mice and transgenic mice expressing full-length α-syntrophin. These in vivo mouse studies highlight the functional importance of appropriate membrane targeting of nNOS by the dystrophin-associated protein α-syntrophin and may have implications for the development of potential gene therapy strategies to treat muscular dystrophy or other muscle-related diseases.

Original languageEnglish (US)
Pages (from-to)554-560
Number of pages7
JournalCirculation research
Volume92
Issue number5
DOIs
StatePublished - Mar 21 2003

Fingerprint

Nitric Oxide Synthase Type I
Nitric Oxide
Skeletal Muscle
Transgenic Mice
PDZ Domains
Vasoconstriction
Muscles
Adrenergic Agents
Dystrophin-Associated Proteins
Sarcolemma
Dystrophin
Muscular Dystrophies
Skeletal Muscle Fibers
Microvessels
Genetic Therapy
syntrophin
Membranes

All Science Journal Classification (ASJC) codes

  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

Thomas, Gail D. ; Shaul, Philip W. ; Yuhanna, Ivan S. ; Froehner, Stanley C. ; Adams, Marvin E. / Vasomodulation by skeletal muscle-derived nitric oxide requires α-syntrophin-mediated sarcolemmal localization of neuronal nitric oxide synthase. In: Circulation research. 2003 ; Vol. 92, No. 5. pp. 554-560.
@article{392e4db25dff4bc6868337b2421edcce,
title = "Vasomodulation by skeletal muscle-derived nitric oxide requires α-syntrophin-mediated sarcolemmal localization of neuronal nitric oxide synthase",
abstract = "Neuronal nitric oxide synthase (nNOS) is abundantly expressed in skeletal muscle where it associates with the dystrophin complex at the sarcolemma by binding to the PDZ domain of α-syntrophin. Nitric oxide (NO) produced by skeletal muscle nNOS is proposed to regulate blood flow in exercising muscle by diffusing from the skeletal muscle fibers to the nearby microvessels where it attenuates α-adrenergic vasoconstriction. In the present study, we hypothesized that sarcolemmal localization of nNOS is a critical determinant of the vasoregulatory effect of skeletal muscle-derived NO. To test this hypothesis, we performed experiments in α-syntrophin null mice and in transgenic mice expressing a mutated α-syntrophin lacking the PDZ domain (ΔPDZ), both of which are characterized by reduced sarcolemmal nNOS. We found that modulation of α-adrenergic vasoconstriction was greatly impaired in the contracting muscles of the α-syntrophin null mice and transgenic ΔPDZ mice compared with wild-type mice and transgenic mice expressing full-length α-syntrophin. These in vivo mouse studies highlight the functional importance of appropriate membrane targeting of nNOS by the dystrophin-associated protein α-syntrophin and may have implications for the development of potential gene therapy strategies to treat muscular dystrophy or other muscle-related diseases.",
author = "Thomas, {Gail D.} and Shaul, {Philip W.} and Yuhanna, {Ivan S.} and Froehner, {Stanley C.} and Adams, {Marvin E.}",
year = "2003",
month = "3",
day = "21",
doi = "10.1161/01.RES.0000061570.83105.52",
language = "English (US)",
volume = "92",
pages = "554--560",
journal = "Circulation Research",
issn = "0009-7330",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

Vasomodulation by skeletal muscle-derived nitric oxide requires α-syntrophin-mediated sarcolemmal localization of neuronal nitric oxide synthase. / Thomas, Gail D.; Shaul, Philip W.; Yuhanna, Ivan S.; Froehner, Stanley C.; Adams, Marvin E.

In: Circulation research, Vol. 92, No. 5, 21.03.2003, p. 554-560.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Vasomodulation by skeletal muscle-derived nitric oxide requires α-syntrophin-mediated sarcolemmal localization of neuronal nitric oxide synthase

AU - Thomas, Gail D.

AU - Shaul, Philip W.

AU - Yuhanna, Ivan S.

AU - Froehner, Stanley C.

AU - Adams, Marvin E.

PY - 2003/3/21

Y1 - 2003/3/21

N2 - Neuronal nitric oxide synthase (nNOS) is abundantly expressed in skeletal muscle where it associates with the dystrophin complex at the sarcolemma by binding to the PDZ domain of α-syntrophin. Nitric oxide (NO) produced by skeletal muscle nNOS is proposed to regulate blood flow in exercising muscle by diffusing from the skeletal muscle fibers to the nearby microvessels where it attenuates α-adrenergic vasoconstriction. In the present study, we hypothesized that sarcolemmal localization of nNOS is a critical determinant of the vasoregulatory effect of skeletal muscle-derived NO. To test this hypothesis, we performed experiments in α-syntrophin null mice and in transgenic mice expressing a mutated α-syntrophin lacking the PDZ domain (ΔPDZ), both of which are characterized by reduced sarcolemmal nNOS. We found that modulation of α-adrenergic vasoconstriction was greatly impaired in the contracting muscles of the α-syntrophin null mice and transgenic ΔPDZ mice compared with wild-type mice and transgenic mice expressing full-length α-syntrophin. These in vivo mouse studies highlight the functional importance of appropriate membrane targeting of nNOS by the dystrophin-associated protein α-syntrophin and may have implications for the development of potential gene therapy strategies to treat muscular dystrophy or other muscle-related diseases.

AB - Neuronal nitric oxide synthase (nNOS) is abundantly expressed in skeletal muscle where it associates with the dystrophin complex at the sarcolemma by binding to the PDZ domain of α-syntrophin. Nitric oxide (NO) produced by skeletal muscle nNOS is proposed to regulate blood flow in exercising muscle by diffusing from the skeletal muscle fibers to the nearby microvessels where it attenuates α-adrenergic vasoconstriction. In the present study, we hypothesized that sarcolemmal localization of nNOS is a critical determinant of the vasoregulatory effect of skeletal muscle-derived NO. To test this hypothesis, we performed experiments in α-syntrophin null mice and in transgenic mice expressing a mutated α-syntrophin lacking the PDZ domain (ΔPDZ), both of which are characterized by reduced sarcolemmal nNOS. We found that modulation of α-adrenergic vasoconstriction was greatly impaired in the contracting muscles of the α-syntrophin null mice and transgenic ΔPDZ mice compared with wild-type mice and transgenic mice expressing full-length α-syntrophin. These in vivo mouse studies highlight the functional importance of appropriate membrane targeting of nNOS by the dystrophin-associated protein α-syntrophin and may have implications for the development of potential gene therapy strategies to treat muscular dystrophy or other muscle-related diseases.

UR - http://www.scopus.com/inward/record.url?scp=0037459338&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037459338&partnerID=8YFLogxK

U2 - 10.1161/01.RES.0000061570.83105.52

DO - 10.1161/01.RES.0000061570.83105.52

M3 - Article

C2 - 12600881

AN - SCOPUS:0037459338

VL - 92

SP - 554

EP - 560

JO - Circulation Research

JF - Circulation Research

SN - 0009-7330

IS - 5

ER -